Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Cobicistat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    J&J seeks expanded approvals for paediatric HIV-1 therapy
    J&J seeks expanded approvals for paediatric HIV-1 therapy

    05 Jun 2024

    // PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/johnson-johnson-approvals-hiv-1/

    PHARMACEUTICAL TECHNOLOGY
    05 Jun 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets
    FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets

    15 Jun 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-tablets-59973.pdf

    FDA
    15 Jun 2023
    Share Share
    Fore Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394
    Fore Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394

    12 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220912005184/en

    BUSINESSWIRE
    12 Sep 2022
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Symtuza 210455 (Darunavir, Cobicistat, Emtricitabine, Tenofovir Alefenamide) 80mg/ 150mg/ 200mg/ 10mg tablets
    FDA Confirms Paragraph IV Patent Challenge of Symtuza 210455 (Darunavir, Cobicistat, Emtricitabine, Tenofovir Alefenamide) 80mg/ 150mg/ 200mg/ 10mg tablets

    06 Oct 2021

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-symtuza-210455-darunavir-cobicistat-emtricitabine-tenofovir-alefenamide-80mg-150mg-200mg-10mg-tablets-1633682776.pdf

    FDA
    06 Oct 2021
    Share Share
    J&J-backed AIDS film picked up by Verizon Media
    J&J-backed AIDS film picked up by Verizon Media

    10 May 2019

    // Beth Snyder Bulik FIERCE PHARMA

    https://www.fiercepharma.com/marketing/j-j-sponsored-film-about-first-aids-ward-san-francisco-picked-up-for-broader-distribution

    Beth Snyder Bulik FIERCE PHARMA
    10 May 2019
    Share Share
    Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen
    Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen

    11 Apr 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/janssen-presents-new-data-from-first-phase-3-trial-of-a-single-tablet-regimen-in-a-rapid-initiation-model-of-care-demonstrating-safety-and-efficacy-with-symtuza-through-48-weeks-300830670.html

    PR NEWSWIRE
    11 Apr 2019
    Share Share